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Editorial on the Research Topic
Redox and Nitrosative Signaling in Cardiovascular System: From Physiological Response to
Disease
Reactive oxygen species (ROS) are highly reactive substances generated by the chemical utilization
of oxygen inside the cells. High levels of ROS induce macromolecule damage leading to a variety
of diseases, but controlled ROS generation play a role in redox-sensitive gene expression and cell
signaling regulating physiological processes including cardiovascular functions.
The main scope of the present special issue was to reach a broad audience of scientists
working in the field of cardiovascular redox biomedicine. We encouraged the submission of
papers approaching the topic from different points of view and at different levels, from basic to
translational research. Indeed, a collection of scientific reports and review articles with different
approaches contributed to the special issue highlighting interesting aspects of redox biology in
several cardiovascular fields. In addition, the research topic includes an intriguing hypothesis article
by Davies reporting that adaptation of the cardiovascular system to exercise training is one of
the most significant examples of adaptive homeostasis: defined as “The transient expansion or
contraction of the homeostatic range in response to exposure to sub-toxic, non-damaging, signaling
molecules or events, or the removal or cessation of such molecules or events.” Endurance training
involves the generation of low levels of free radicals and hydrogen peroxide which do not cause
damage, but rather activate signal transduction pathways, such as Nrf2 and NFκB, to induce
mitochondrial biogenesis—the foundation of increased exercise endurance. As with other examples
of adaptive homeostasis, the effects are transient, lasting only as long as the training is maintained.
Unfortunately, the ability to adapt to exercise training declines with age, perhaps as a result of
impaired Nrf2 and NFκB signaling, as does adaptive homeostasis capacity in general.
Several original articles and reviews included in the special issue emphasize the role of
mitochondria in cardiac activity both in physiologic and pathological conditions. The mini-review
by Pagliaro et al. deals with the role of mitochondria in ischemic and pharmacological cardiac
postconditioning. The main interesting aspect of this work is the deepening of the signaling
pathways converging on mitochondria able to preserve many of the mitochondrial functions
after ischemia/reperfusion. In particular, the role of mitochondrial components like connexin 43,
mitochondrial KATP channels and mitochondrial permeability transition pore in cardioprotective
effects of postconditioning are widely highlighted. Another review article by Penna et al. examines
the role of chaperones in the heart and the redox aspects that can influence cardiac chaperone
function, especially within mitochondria. Chaperones are stress proteins involved in the adaptive
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response to stress conditions and in this review are discussed
the redox-dependent regulation of chaperones underlying the
cardiac ischemia/reperfusion injury as well as cardioprotection.
The original article by Boengler et al. point outs that
depending on their amounts, reactive oxygen species (ROS)
may either be detrimental [in myocardial ischemia/reperfusion
(IR) injury] or protective (ischemic preconditioning, IPC).
Here, the authors addressed the role of the ROS-producing
enzyme p66shc in IR and IPC. Following IR (not IPC), p66shc
translocated into cardiac subsarcolemmal mitochondria and
this was associated with increased ROS formation. However,
p66shc-deficient hearts showed similar infarct sizes after IR
and effective cardioprotection by IPC suggesting that p66shc-
derived ROS do not contribute to IR injury per se and are
not involved in the cardioprotection by IPC. Schiattarella
et al. showed that animals with mitochondrial A-kinase anchor
protein (AKAP1) knockdown or knockout are more sensitive
to TAC, an experimental model to induce pressure overload,
heart hypertrophy, cardiomyocyte apoptosis and heart failure.
Indeed, animals Akap 1−/− showed increased levels of ROS,
apoptotic markers such as short caspase-3, and TUNEL
positive cells in cardiac tissues. In particular, authors discussed
that aforementioned TAC-effects may be correlated with the
AKT/NO signaling, given that TAC-induced AKT signaling
activation is blunted in animals knock-out for AKAP1.
Several contributions point out the mechanisms of drugs that
affect cardiovascular system targeting redox signaling pathways.
The review by Varricchi et al. deals with cardiovascular toxicity
(CTX) by chemotherapeutic agents which can alter redox
homeostasis by increasing the production of ROS and reactive
nitrogen species (RNS). The article reports that mitochondria are
central targets for chemotherapeutic-induced CTX. The authors
underline that, though, the last decade has witnessed intense
research related to the molecular and biochemical mechanisms
of CTX of antineoplastic drugs, experimental and clinical studies
are urgently needed to balance safety and efficacy of novel cancer
therapies. In this line, the paper by Riccio et al. demonstrates
that the Na+ current inhibitor, ranolazine, is able to attenuate
heart dysfunction induced by trastuzumab in animal and cellular
models. The authors suggest that the cardioprotective role of
ranolazine might be due to the blunting of ROS production
induced by trastuzumab, as demonstrated in vitro. About drugs
with cardioprotective effects, the work by Vieceli Dalla Sega et al.
demonstrates that ticagrelor is able to lower circulating epidermal
growth factor (EGF) which, in turn, leads to a better generation
of NO in the vascular endothelium. The authors suggest that the
capacity of ticagrelor in stabilizing platelets is also responsible
for the lower release of EGF by platelets through a mechanism
mediated by P2Y12. Taken together, data here presented
indicate that–in addition to previously identified mechanisms
like augmented adenosine bioavailability-the improvement of
ticagrelor of endothelial function may depend on its greater
efficacy in decreasing platelet reactivity. Interestingly, Russo et al.
report a cardioprotective role for healthy platelets mediated by
sphingosine-1-phosphate-dependent pathways, in the context of
myocardial I/R. This cardioprotective effect is lost by platelets
derived from poorly controlled diabetic patients and seems
inversely correlated with the redox status and the reactivity of
platelets. Antiplatelet agents might exploit the cardioprotective
potentialities of platelets. Varga et al. in their original article
suggest a role for NADPH oxidase (NOX) in ROS production
during heart failure. They report that NOX4 undergoes extensive
alternative splicing in human hearts, which gives rise to
the expression of different enzyme isoforms. In particular,
the full-length NOX4 is significantly upregulated in ischemic
cardiomyopathy. These results may revive the development of
NOX inhibitors based on the significant novel knowledge on the
modulation of NOX activity, which may facilitate the targeting
of NOXs in various diseases including myocardial infarction.
Interestingly, Nydegger et al. in their elegant research work
have shown that in the hypoxia-mediated model of pulmonary
hypertension, modulation of the NO-cGMP pathway by sildenafil
contrasts pulmonary vascular and right ventricle remodeling
by an action that does not only encompass the canonical
vasomodulatory effect but involves the modulation of several
biochemical pathways. The potential role of phosphodiesterase-5
for long-term treatment, and perhaps prevention, of pulmonary
hypertension is suggested and it is surely worthy of further
investigation. The interesting original article by Rocca et al.
demonstrates the cardioprotective role of the G protein-coupled
estrogen receptor (GPER) expressed in the cardiovascular
system, and of its selective ligand G1 through Notch signaling
pathways in female hearts. The main finding of the study is
the role of GPER in mediating the preconditioning mechanisms
in normotensive and hypertensive conditions that protect the
myocardium from I/R injury. G1-induced protection open new
perspectives in the treatment of the myocardial ischemic injury.
In their original article, Andreadou et al. show that empagliflozin
(EMPA), a drug approved for type 2 diabetes management,
reduces infarct size after I/R in mice and increase cell survival
and ATP levels in rat embryonic-heart-derived cardiomyoblasts
(H9C2) and endothelial cells (ECs). The protective effects of
EMPA in mice are dependent on STAT3 activation and seem
associated with reduced levels of malondialdehyde, myocardial
iNOS, and interleukin-6 expression.
Recently, a great effort has been made to clarify the role of
natural substances and/or antioxidants taken with diet or as
food suppliers, in the prevention or treatment of cardiovascular
diseases. On this topic, Sorriento et al. focus on antioxidants
and in particular on vitamin D as anti-hypertensive agents.
Arterial hypertension seems to depend on an imbalance between
the production of ROS/RNS and the antioxidant defense
mechanisms. The association between vitamin D deficiency
and hypertension is strongly supported by literature suggesting
that the supplementation of vitamin D could really become a
therapeutic strategy for hypertension if an accurate selection of
patients will be made. The authors propose that PTH levels,
that regulate and are regulated by vitamin D, could be an
important discriminating parameter in the selection of patients
that could be sensitive to vitamin D supplementation. Thus,
according to authors, vitamin D represents an antioxidant
that is worthwhile to further investigate. Another compound
that deserves to be studied is the melatonin. In their review
article, Jiki et al. critically discuss the cardiovascular benefits
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of dietary melatonin. The authors report and discuss the
papers on the effects of melatonin in different conditions,
including hypertension and I/R injury. The issue at moment
is: how can we increase the level of melatonin in human
blood? Preclinical studies suggest that melatonin, given at
dietary levels, confers cardioprotection. Circulating melatonin
levels may have antioxidant capacity. However, there are many
contradictory observations, still requiring responses. The original
paper by Mastantuono et al. describes the effects of another
natural antioxidant, the anthocyanin cyanidin. Studying rat pial
microvascular changes due to cerebral blood flow reduction
and recovery, the authors describe the protective mechanisms
of this compound. Based on the results, they conclude that
cyanidin protects cerebral microvasculature against vascular
insult. Protection is elicited by recruiting the NO generation
and a reducing ROS generation, thus preserving vascular
permeability and vasodilation. Many pathological conditions,
including hyperglycemia, may alter endothelial function through
ROS/RNS overproduction. The paper by Querio et al. shows the
antioxidant properties of chamazulene, a bioactive compound
present in chamomile essential oil, in bovine aortic endothelial
cells exposed to high glucose, and hydrogen peroxide-mediated
oxidative stress. Their data suggest a possible use of this
compound as a protective agent against endothelial injury.
The connection between cardiovascular system dysfunction
and neurodegeneration is highlighted by Venturelli et al. that
emphasize the importance of changes in NO bioavailability,
cortical, extra-cranial, and peripheral blood flow in patients with
Alzheimer’s Disease (AD). The authors believe that these are
phenomena primarily associated with AD and are not simply
correlated with aging. Indeed, a relationship between AD and
vascular impairment till to the more advanced phases of AD
is described. Therefore, the link between cardiovascular and
the central nervous system degenerative processes may be the
depletion of endogenous NO. Since current AD treatments
targeting Aß show very limited efficacy, potential new therapeutic
approaches aimed to ameliorate the circulatory impairment and
the depletion of NO bioavailability might be of pivotal interest for
AD, and may reduce the high costs of patients’ care. The study
by Firinu et al. expands this concept by showing a significant
decrease in endothelial function in another pathologic condition,
namely the hereditary angioedema (HAE). In these patients,
during the symptom-free period, a strong correlation between
flow-mediated dilatation and asymmetric dimethylarginine, a
strong inhibition of NO synthesis, was observed. This is in line
with the described association of HAE and early atherosclerosis.
The topic includes also other two articles that deal with
central nervous system diseases, emphasizing the cardiovascular
aspects and the link with oxidative stress. In their mini-review,
Paternò and Chillon discuss the similarity between two diseases
of the CNS, ischemic stroke, and multiple sclerosis focusing
especially on the astrocyte and neuroinflammation hallmarks
shared by the two pathologies. Interestingly, the mini-review
also highlight the astrocyte and neuroinflammation-targeted-
strategies for the treatment of stroke and multiple sclerosis.
The paper by Messina et al. suggests the need to broaden
horizons and the study target on Autism spectrum disorders
(ASD), including oxidative stress, neurotransmitters evaluation,
and sympathetic activity measurements also related to cardiac
functions. Sleep problems in ASD are a prominent feature,
considering the role of orexins (A and B) in wake-sleep circadian
rhythm, it is possible to speculate that ASD subjects may present
a dysregulation in orexinergic neurotransmission. In this context
may be explained the cerebral metabolism increasing and the
autonomic hyperfunctioning in ASD sustained by high Orexin
A levels.
Finally, in the special issue are included two reviews that may
open new perspectives. In their interesting review article, Deidda
et al. report several studies adopting ametabolomic approach that
eventually could be helpful in elucidating mechanisms involved
in redox and nitrosative reactions in relation to cardiovascular
disease. These pieces of informationmay be of significant interest
for both translational values and for improving an update of the
protocols on metabolomics methods in cardiovascular diseases.
By referring to teleost fish as paradigms of hypoxia- and anoxia-
tolerance, Gattuso et al. illustrate cardiac strategies that, by
involving nitric oxide and its metabolites, play a critical role in
the adaptive responses to O2 limitation. Authors emphasize the
power of the teleost heart as a bioassay to decipher the intricate
molecular networks that crucially balance tissue O2 supply and
demand. Information in this direction may be of significance also
in a translational perspective for human cardioprotection and
perhaps in hypoxia-mediated pulmonary hypertension.
The above-referenced articles are a clear demonstration that
the research topic reached the aim of presenting the point of view
of many scientists working in the field of redox biomedicine. The
papers approached the topic from different points of view and
at different levels, from basic to translational research. We hope
these articles can contribute to the development of new ideas and
advancements in the field of redox and nitrosative signaling in the
control of normal cardiovascular functions and their disruption
in diseases.
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